A Phase 1 Study of ADI-001 in B Cell Malignancies

Study Number
3214822
Phase
I
Age Group
Adult
Principal Investigator
Matthew Cortese
Purpose

This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.

Check your eligibility for this trial
Check now
Full Title

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta T Cells in Adults with B Cell Malignancies

ClinicalTrials.Gov ID
NCT04735471

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.